CMX157 decreased circulating levels of tenofovir, lowered systemic exposure and reduced the potential for renal and bone side effects."
Unfortunately, the reports by these financial advisors/reporters frequently lack the necessary precision. In this case the difference would be critical. I am not sure at this point what to trust, since in some presentations the company actually seemingly used simple Tenofovir, not TDF as a comparison drug.
It is an effective antiviral agent but is limited by low oral bioavailability, renal toxicity and poor cell penetration. According to the company, CMX157's novel formulation enables it to deliver high intracellular concentrations of tenofovir thereby making it more effective at permanently suppressing HBV replication than existing drugs.
hiv use of tenofovir is not to be considered because hiv damages kidneys too, on hbv trials kidney toxicity is no issue since only 1% developped toxicity and lowering tenofovir dose resolve this and tenofovir is still very active on hbv.unfortunately there is no research on optimal dose of tenofovir on hbv without sides (tenofovir is produced by gilead and they wanted to push use of hespera and probably hiden tenofovir from 2001...
As GS-7340 is more efficacious than tenofovir do you think that by its approval(hope soon as studies are underway in Hiv patients) will lead to the approval of this drug for Hepatitis B and are we expecting more hbv seroconversions(used in combo or mono)?
Waiting for any answers.
hbv has no symptoms, you may even be dying and feel nothing
tenofovir improves kideys function especially tenofovir+telbivudine in those with kidneys function.
//www.medhelp.
if you have renal problems i would monitor and switch to entecavir if they get worse or stay out of range.there is many people here taking tenofovir for years, check what is their experience on this
talk with the doctor about switching to etv, did you have renal problems before starting tx?
in case of decline of gfr below 60 or 30, since renal failure is when gfr is below 15, tenofovir can be reduced to 150mg daily or 75mg daily and still fully active.at lower doses the drug still works even in case of lamR, i posted a study a couple of days ago on this who last 5 years without any tdf resistance, both doses are much more potent than adv
since only 1% needs to change dose due to low gfr below 30 it is better to keep full dose even if 150mg and 75mg work.
Both etv and tdf have to be processed through renal tubes so both can impact kidneys but most people are ok. The Tenofovir TAF is supposed to be very good.
3. Entecavir in high doses in animal studies was causing cancer but no human cases reported yet.
4. Tenofovir has a stonger resistsnce profile for mutants.
There is two tenofovirs, TDF and TAF. TAF is the new one.
Your only reasonable choice is tenofovir. Despite its chemical similarity, tenofovir is about 80 times less toxic to the kidneys than adefovir.
I remember a personal discussion about this with Gileads research director, Gibbs, at the time. He said "we had no idea, what a huge difference a single methyl group can make".
i was checking if there is anyway to prevent kidneys damage in cases like mine where kidenys cannot stand tenofovir, i don t have plans to add tenofovir for the moment but in any case i'd like to make sure i will be able to use it if ever needed.
this is what i have found,there are 3 antioxidants that help prevent kidneys damage:
co-q10, looks like the most potent since it has been used in patients with severe renal failure.Co Q10 for chronic renal failure
http://findarticles.
He was an ingenious organic chemist, developed first adefovir, then, together with de Clerq in Belgium Tenofovir a compound which has only one Methyl group additional attached to Adefovir, which was surprisingly reducing its toxicity by at least 50fold.
Due to the extremely low susceptibility to resistance and very low toxicity this drug became the cornerstone of antiviral treatment for HIV and HBV.
Due to the risk of life-threatening and fatal toxicity, patients with renal or hepatic impairment should not be given colchicine in combination with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, voriconazole, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics. In patients with normal renal and hepatic function, the dosage of colchicine should be reduced when used with potent CYP450 3A4 inhibitors or within 14 days of using them.
It has a high rate of drug resistance and toxicity than todays first line drugs entecavir and tenofovir. It can never Cure hbv except rarely where individuals are naturally proned to clear the infections.
Honestly there is no certain cure for hbv today and atleast will not be till next 2-3 years for sure.
Recommended
